Blueprint Medicines Corp (NAS:BPMC)
$ 102.81 0.42 (0.41%) Market Cap: 6.44 Bil Enterprise Value: 6.09 Bil PE Ratio: 0 PB Ratio: 20.73 GF Score: 72/100

Blueprint Medicines Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 04:30PM GMT
Release Date Price: $75.98 (+4.08%)
David Neil Lebowitz;Jeffrey W. Albers
Morgan Stanley, Research Division - VP;Blueprint Medicines Corporation - CEO, President & Director<

Good afternoon. I'd like to welcome you again to the Morgan Stanley 18th Annual Global Health Care Conference. Before we get started, I have to go through the requisite disclosures. Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

I'm happy to have with us in our current session here from Blueprint Medicines, CEO, Jeff Albers. I guess if you could start by giving us a top line description of Blueprint Medicines, what your overall mission is?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot